584 related articles for article (PubMed ID: 16519745)
1. Low-molecular-weight heparins and angiogenesis.
Norrby K
APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
[TBL] [Abstract][Full Text] [Related]
2. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin.
Marchetti M; Vignoli A; Russo L; Balducci D; Pagnoncelli M; Barbui T; Falanga A
Thromb Res; 2008; 121(5):637-45. PubMed ID: 17692905
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence.
Mousa SA; Petersen LJ
Thromb Haemost; 2009 Aug; 102(2):258-67. PubMed ID: 19652876
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin in thrombosis and cancer.
Mousa SA
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():25-30. PubMed ID: 15085463
[TBL] [Abstract][Full Text] [Related]
5. Clinical studies with anticoagulants to improve survival in cancer patients.
Gerotziafas GT; Papageorgiou C; Hatmi M; Samama MM; Elalamy I
Pathophysiol Haemost Thromb; 2008; 36(3-4):204-11. PubMed ID: 19176993
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotics in thrombosis and cancer.
Mousa SA
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):283-91. PubMed ID: 15030287
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulants in thrombosis and cancer: the missing link.
Mousa SA
Semin Thromb Hemost; 2002 Feb; 28(1):45-52. PubMed ID: 11885025
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulants in thrombosis and cancer: the missing link.
Mousa SA
Expert Rev Anticancer Ther; 2002 Apr; 2(2):227-33. PubMed ID: 12113244
[TBL] [Abstract][Full Text] [Related]
9. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
10. The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer.
Lee AY
Thromb Res; 2007; 120 Suppl 2():S121-7. PubMed ID: 18023705
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotics in thrombosis and cancer.
Mousa SA
Hamostaseologie; 2005 Nov; 25(4):380-6. PubMed ID: 16395488
[TBL] [Abstract][Full Text] [Related]
12. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro.
Collen A; Smorenburg SM; Peters E; Lupu F; Koolwijk P; Van Noorden C; van Hinsbergh VW
Cancer Res; 2000 Nov; 60(21):6196-200. PubMed ID: 11085545
[TBL] [Abstract][Full Text] [Related]
13. Heparanase, heparin and the coagulation system in cancer progression.
Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
[TBL] [Abstract][Full Text] [Related]
14. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin.
Young E; Wells P; Holloway S; Weitz J; Hirsh J
Thromb Haemost; 1994 Mar; 71(3):300-4. PubMed ID: 8029793
[TBL] [Abstract][Full Text] [Related]
15. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence.
Cosgrove RH; Zacharski LR; Racine E; Andersen JC
Semin Thromb Hemost; 2002 Feb; 28(1):79-87. PubMed ID: 11885028
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?
Burris HA
Semin Oncol; 2006 Apr; 33(2 Suppl 4):S3-16; quiz S41-2. PubMed ID: 16638456
[TBL] [Abstract][Full Text] [Related]
17. Non-anti-coagulant heparins: a promising approach for prevention of tumor metastasis (review).
Kragh M; Loechel F
Int J Oncol; 2005 Oct; 27(4):1159-67. PubMed ID: 16142335
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
19. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties.
Vignoli A; Marchetti M; Balducci D; Barbui T; Falanga A
Haematologica; 2006 Feb; 91(2):207-14. PubMed ID: 16461305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
